Lack of preclinical support for the efficacy of histone deacetylase inhibitors in the treatment of psoriasis

British Journal of Dermatology

Volumn 174, Issue 2, 2016, Pages 424-426

  Ekman, A K ^a   Enerbäck, Charlotta ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPSORIASIS AGENT; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; DERMATOLOGICAL AGENT;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; DEACETYLATION; DEGENERATIVE DISEASE; DENDRITIC CELL; DRUG EFFICACY; EPIDERMIS; EPIGENETICS; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; IN VITRO STUDY; INFLAMMATION; KERATINOCYTE; LETTER; NEOPLASM; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PSORIASIS; PUNCH BIOPSY; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SKIN BIOPSY; SYNOVIOCYTE; CASE CONTROL STUDY; ENZYMOLOGY; METABOLISM; MONONUCLEAR CELL; SKIN;

CASE-CONTROL STUDIES; DERMATOLOGIC AGENTS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; LEUKOCYTES, MONONUCLEAR; PSORIASIS; SKIN;

EID: 84947316325     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.14021     Document Type: Letter

References (15)

1. Newbold A, Matthews GM, Bots M, et al,. Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities. Mol Cancer Ther 2013; 12: 2709-21.
2. Li J, Li G, Xu W,. Histone deacetylase inhibitors: an attractive strategy for cancer therapy. Curr Med Chem 2013; 20: 1858-86.
3. Shanmugam MK, Sethi G,. Role of epigenetics in inflammation-associated diseases. Subcell Biochem 2013; 61: 627-57.
4. Gillespie J, Savic S, Wong C, et al,. Histone deacetylases are dysregulated in rheumatoid arthritis and a novel histone deacetylase 3-selective inhibitor reduces interleukin-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Rheum 2012; 64: 418-22.
5. Hawtree S, Muthana M, Wilson AG,. The role of histone deacetylases in rheumatoid arthritis fibroblast-like synoviocytes. Biochem Soc Trans 2013; 41: 783-8.
6. Leoni F, Zaliani A, Bertolini G, et al,. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 2002; 99: 2995-3000.
7. Falkenberg KJ, Johnstone RW,. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 2014; 13: 673-91.
8. Saunders N, Dicker A, Popa C, et al,. Histone deacetylase inhibitors as potential anti-skin cancer agents. Cancer Res 1999; 59: 399-404.
9. Kwon HJ, Kim MS, Kim MJ, et al,. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int J Cancer 2002; 97: 290-6.
10. McLaughlin F, La Thangue NB,. Histone deacetylase inhibitors in psoriasis therapy. Curr Drug Targets Inflamm Allergy 2004; 3: 213-19.
11. Toussirot E, Abbas W, Khan KA, et al,. Imbalance between HAT and HDAC activities in the PBMCs of patients with ankylosing spondylitis or rheumatoid arthritis and influence of HDAC inhibitors on TNF alpha production. PLoS ONE 2013; 8: e70939.
12. Glozak MA, Seto E,. Histone deacetylases and cancer. Oncogene 2007; 26: 5420-32.
13. Wang Y, Miao X, Liu Y, et al,. Dysregulation of histone acetyltransferases and deacetylases in cardiovascular diseases. Oxid Med Cell Longev 2014; 2014: 641979.
14. Tang J, Yan H, Zhuang S,. Histone deacetylases as targets for treatment of multiple diseases. Clin Sci (Lond) 2013; 124: 651-62.
15. Tovar-Castillo LE, Cancino-Diaz JC, Garcia-Vazquez F, et al,. Under-expression of VHL and over-expression of HDAC-1, HIF-1alpha, LL-37, and IAP-2 in affected skin biopsies of patients with psoriasis. Int J Dermatol 2007; 46: 239-46.